MKI67 and neoplasm: Variations in proliferative index scores were observed, with 32.6% of patients having primary and disseminated tumors scoring within all three categories, and 45.6% of patients with scores in two categories (Figure 5E), suggesting that the assessment of Ki67 as an accurate prognostic biomarker for HGSOC is confounded by extensive variation between tumor sites.